Stanford Cancer Institute News
Stanford Cancer Institute News is a quarterly update for members, supporters and friends. On behalf of our members and staff, we thank you for your ongoing support and welcome your feedback and inquiries.
Featured Articles from the Current Issue
The Fastest-Ever Medical Linear Accelerator Could Revolutionize Cancer Treatment
PHASER: Next-generation Radiation Therapy
Today, the quickest radiation treatments for cancer take several minutes per session. A large and clunky linear accelerator, which produces radiation, must mechanically rotate around a patient’s body, hitting a tumor from many angles as it bombards the cells in its path with high-energy beams. During that time—which can be as long as an hour and a half in some cases—it’s a given that the tumor will move at least slightly.
First FDA-Approved Treatment for Chronic Graft Versus Host Disease
The work of Stanford researchers has led to the first-ever approval from the Food and Drug Administration (FDA) for a drug to treat graft versus host disease (GVHD)—a potentially serious complication of hematopoietic cell transplants that utilize cells from a donor not related to the transplant recipient. Hematopoietic cell and bone marrow transplants (collectively referred to as HCT transplants) are used to treat some blood and bone marrow and other select cancers. Until now, doctors relied on corticosteroids to treat GVHD, but the long-term use of steroids causes many side effects, and GVHD frequently re-emerges when steroids are stopped.
30 Years of BMT
The Stanford Blood and Marrow Transplant (BMT) Program celebrates 30 years of treating patients this fall. The program—the largest in Northern California—has been the designated provider for Kaiser Permanente in Northern California for over 20 years. It is also one of 20 programs nationwide to be named a Core Clinical Center for the NCI’s Blood and Marrow Transplant Clinical Trials Network.
Clinical Trial Advances Treatment Of Neuroendocrine Tumors
SCI Researchers Help Show Efficacy of New Cancer Drug
Patients with advanced neuroendocrine tumors (NETs) may soon have a new treatment option, thanks to research conducted with support from the SCI. The phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial, which involved SCI researchers, concluded that the drug 177Lu DOTATATE lengthened survival of patients with small intestine NETs by nearly three years. The results were published in the January 2017 issue of the New England Journal of Medicine.